Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin's lymphoma,
is clinically heterogeneous: 40% of patients respond well to current therapy and have …

Background Despite advances in treatments for Hodgkin's lymphoma, about 20% of
patients still die from progressive disease. Current prognostic models predict the outcome of …

Diffuse large B-cell lymphoma (DLBCL) can be divided into prognostically important
subgroups with germinal center B-cell–like (GCB), activated B-cell–like (ABC), and type 3 gene …

Background The role of BCL2 as a predictor of survival in diffuse large B-cell lymphoma (DLBCL)
is controversial. DLBCL is heterogeneous, and the expression of BCL2 is variable …

Peripheral T cell lymphomas (PTCLs) are a heterogeneous group of orphan neoplasms.
Despite the introduction of anthracycline-based chemotherapy protocols, with or without …

A role for B-cell-receptor (BCR) signalling in lymphomagenesis has been inferred by studying
immunoglobulin genes in human lymphomas 1 , 2 and by engineering mouse models 3 , …

The activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) remains
the least curable form of this malignancy despite recent advances in therapy 1 . Constitutive …

Diffuse large B cell lymphoma (DLBCL) is the most common form of non-Hodgkin's lymphoma.
In the least curable (ABC) subtype of DLBCL, survival of the malignant cells is dependent …

Burkitt’s lymphoma (BL) can often be cured by intensive chemotherapy, but the toxicity of
such therapy precludes its use in the elderly and in patients with endemic BL in developing …

Peripheral T-cell lymphoma (PTCL) encompasses a heterogeneous group of neoplasms with
generally poor clinical outcome. Currently 50% of PTCL cases are not classifiable: PTCL-…